Chadwick Jeremy G

Chadwick Jeremy G, Chief Operating Officer of Kymera Therapeutics (KYMR), has been a consistent seller of company stock over the past several months, with no open-market purchases recorded in his recent Form 4 filings. Across 41 total transactions, all of his activity has been concentrated in KYMR, totaling roughly $15.6 million in sales. The pattern is heavily skewed toward disposition: 17 recent sales, zero buys, and no acquisitions through open-market purchases. The sales are often paired with option exercises (coded "M"), which are mechanical in nature, but the subsequent open-market sales (coded "S") represent a clear directional bias toward reducing his stake. The most active period came in late March through late May 2026, with a cluster of sales on March 23, March 25, and March 31 totaling approximately $3.76 million, followed by another wave in late May. On May 26 alone, he sold roughly $1.02 million across five separate transactions, and on May 27 he added another $349,000. These sales were interspersed with option exercises, such as a $732,908 exercise on March 25 and a $433,930 exercise on April 1, which provided the shares for the subsequent dispositions. The largest single sale was $1.99 million on March 25, while smaller sales, like $25,651 on May 26, show a steady drip of liquidation rather than a one-time exit. Notably, there are no "P" (purchase) codes in the data, meaning Chadwick has not added to his position on the open market during this window. The absence of any buying activity, combined with the frequency and size of the sales, suggests a sustained reduction in his KYMR holdings. The transactions are all in a single ticker, indicating his insider activity is entirely tied to Kymera’s performance, with the recent direction firmly bearish from a cash-flow perspective.